Supriya Lifescience Limited — Updates, 14-08-2025: Press Release

Supriya Lifescience reported a revenue decline to Rs 145.07 Cr in the latest quarter, down from Rs 160.63 Cr in the year-ago quarter. PAT also decreased to Rs 34.79 Cr. This dip was attributed to production facility maintenance delays. Despite this, EBITDA margins remained strong at 35.6%. The Anaesthetic segment's revenue contribution grew to 53%, and European markets now contribute 41% of business. Capacity utilization improved to 76%. Management expects a recovery in the second half due to the Ambernath site nearing production and 3-4 new product launches, aiming for robust future growth.